vWF-FVIII Complex Stabilization and Purification

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The challenge lies in efficiently purifying Factor VIII (FVIII) while minimizing its association with Von Willebrand Factor (vWF), as FVIII is often absorbed or degraded during expression, and conventional methods struggle to separate and maintain its stability effectively.

Innovation Solution

A polypeptide comprising a vWF sequence without domains D4, B1, B2, B3, C1, C2, and CK, fused with an immunoglobulin Fc sequence, which forms dimers or multimers with FVIII, allowing for enhanced binding and stability, and can be used to create a protein complex for improved purification and extended plasma half-life.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional chromatographic methods are used to purify FVIII, then FVIII can be separated from vWF, but FVIII is absorbed onto cell surfaces or degraded during expression, reducing yield

Engineering Contradiction:
ImproveFVIII yieldVSAvoidFVIII stability
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent introduces vWF as an intermediary protective agent that binds to FVIII during expression, preventing its absorption onto cell surfaces and degradation. The vWF-FVIII complex serves as a protected intermediate form that can be later dissociated through chromatographic methods, thereby improving both yield and stability of FVIII production

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies preliminary protective action by allowing vWF to bind to FVIII during the expression process before purification occurs. This pre-protection mechanism prevents FVIII from being degraded or absorbed during the critical expression phase, ensuring higher recovery rates in subsequent purification steps

Inventive Principle:
Principle #10Preliminary action

2Reliability

If vWF is used to protect FVIII during expression, then FVIII stability improves, but separation and purification becomes more difficult

Engineering Contradiction:
ImproveFVIII stabilityVSAvoidPurification complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent utilizes parameter changes in pH and ionic strength during chromatographic purification to selectively dissociate the vWF-FVIII complex. By adjusting these parameters, the complex can be separated into pure FVIII and vWF, resolving the purification challenge while maintaining the protective benefits during expression

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent applies extraction principles by selectively removing FVIII from the vWF-FVIII complex through chromatographic separation. The FVIII is extracted from the protective complex under controlled conditions, allowing recovery of pure FVIII while leaving vWF behind for potential reuse

Inventive Principle:
Principle #2Taking out (Extraction)

3Reliability

If full-length vWF is used to form complexes with FVIII, then protection from degradation improves, but purification speed and efficiency decrease

Engineering Contradiction:
ImproveFVIII protectionVSAvoidPurification speed
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent segments the full-length vWF molecule into specific domains (such as D3, A1, A2, A3) that retain the essential FVIII-binding and protective functions. These truncated vWF variants are smaller and easier to purify while maintaining their ability to protect FVIII during expression, thereby improving purification efficiency without sacrificing protection

Inventive Principle:
Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enables robust expression and rapid chromatographic purification of FVIII, protecting it from degradation and enhancing its plasma half-life, thereby improving the yield and purity of FVIII while reducing contamination from vWF.

Implementation Method 1

a polypeptide comprising a vWF sequence without domains D4, B1, B2, B3, C1, C2, and CK, fused with an immunoglobulin Fc sequence, which forms dimers or multimers with FVIII, allowing for enhanced binding and stability

Methodology Applied
Scientific EffectProtein binding: Adsorption

Implementation Method 2

rapid chromatographic purification of FVIII

Methodology Applied
Scientific EffectChromatography: Chromatography

Data Source

PatentEP2499165B1Von willebrand factor (VWF)-containing preparations, and methods, kits, and uses related thereto
Publication Date: 2016.09.14 GRIFOLS THERAPEUTICS INC
  • EP2499165B1 patent drawingFigure 1A~1D
  • EP2499165B1 patent drawingFigure 2A~2C
  • EP2499165B1 patent drawingFigure 3A~3C

AI summary

The present invention relates to methods, compositions and kits for preparing FVIII and employing same. Also provided are vWF polypeptides and nucleic acid molecules encoding same.